241 related articles for article (PubMed ID: 29054321)
21. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Kulkarni AV; Lee J; Reddy KR
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
[TBL] [Abstract][Full Text] [Related]
22. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
[TBL] [Abstract][Full Text] [Related]
23. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
Goyal O; Sidhu SS; Sehgal N; Puri S
J Assoc Physicians India; 2016 Sep; 64(9):30-35. PubMed ID: 27762512
[TBL] [Abstract][Full Text] [Related]
24. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.
Zhang J; Rössle M; Zhou X; Deng J; Liu L; Qi X
Curr Med Res Opin; 2019 May; 35(5):859-868. PubMed ID: 30474439
[TBL] [Abstract][Full Text] [Related]
25. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Duong N; Kakadiya P; Bajaj JS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
[TBL] [Abstract][Full Text] [Related]
26. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
27. Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
Belcher JM
Med Clin North Am; 2023 Jul; 107(4):781-792. PubMed ID: 37258014
[TBL] [Abstract][Full Text] [Related]
28. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
[TBL] [Abstract][Full Text] [Related]
29. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
Rice JP; Skagen C; Said A
Transplantation; 2011 May; 91(10):1141-7. PubMed ID: 21544034
[TBL] [Abstract][Full Text] [Related]
30. Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle I; Laterre PF
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):173-188. PubMed ID: 29258378
[TBL] [Abstract][Full Text] [Related]
31. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
[TBL] [Abstract][Full Text] [Related]
32. Ischemic Skin Necrosis in Hepatorenal Syndrome Patient Secondary to Terlipressin.
Ahmed R; Haseeb A
J Coll Physicians Surg Pak; 2019 Jun; 29(6):S26-S28. PubMed ID: 31142412
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia.
Rey R M; Delgado AF; De Zubiria A; Pinto R; De la Hoz-Valle JA; Pérez-Riveros ED; Ardila G; Sierra-Arango F
PLoS One; 2020; 15(10):e0239834. PubMed ID: 33079947
[TBL] [Abstract][Full Text] [Related]
34. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
35. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
36. [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].
Liu CH; Xing F; Wang J
Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):929-932. PubMed ID: 31941255
[TBL] [Abstract][Full Text] [Related]
37. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
38. Terlipressin vs Midodrine Plus Octreotide for Hepatorenal Syndrome-Acute Kidney Injury: A Propensity Score-Matched Comparison.
Gonzalez SA; Chirikov VV; Wang WJ; Huang X; Jamil K; Simonetto DA
Clin Transl Gastroenterol; 2023 Dec; 14(12):e00627. PubMed ID: 37622521
[TBL] [Abstract][Full Text] [Related]
39. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
40. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
Velez JC; Kadian M; Taburyanskaya M; Bohm NM; Delay TA; Karakala N; Rockey DC; Nietert PJ; Goodwin AJ; Whelan TP
Nephron; 2015; 131(3):191-201. PubMed ID: 26485256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
